You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
In response to CMS reopening its national coverage determination to address its germline testing policy, stakeholders point out areas of concern and confusion.
CMS had received significant stakeholder feedback that germline NGS testing is not the same as somatic testing, and that the NCD as written would negatively impact patients.
The diversity of the organizations that have signed the letter to CMS demonstrates widespread concern over this policy.
CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.